The use of left ventricular assist devices (LVAD) to support non-transplant candidates is controversial. We reviewed a large bridge-to-transplant database and found patients (pts) who were poor transplant candidates by virtue of advanced age or significant end-organ dysfunction. The goal of this analysis was to assess the efficacy of LVAD support in this population. Methods: We retrospectively reviewed the clinical data of the 225 pts enrolled in a US bridge-to-transplant trial. All patients had evidence of cardiogenic shock and high cardiac filling pressures despite optimal medical therapy. High-dose inotropic medications and intraaortic balloon counterpulsation also satisfied inclusion criteria. Low-risk recipients (LRR; n=146) were < 65 years of age and had a BUN < 100 mg/dl, Cr <2.5 mg/dl, bilirubin < 5.0 mg/dl, negative blood cultures and a pulmonary vascular resistance < 480 dyne sec/cm 5 . High-risk recipients (HRR; n=44) had at least one value discordant with those listed above. A control group (Co; n=35) was identified that met LVAD criteria but did not receive a device as a result of pt preference, device unavailability, or a mechanical aortic valve. Intergroup comparisons were analyzed using a student's t-test with p<0.05 considered significant. Kaplan-Meier analysis was used to estimate survival using log-rank test to assess significance. Results: Compared to LRR, the HRR had a lower mean blood pressure (63.9 vs 69.2, p<0.02), a higher pulmonary vascular resistance (282 vs 219, p=0.01), a higher BUN and Cr (52 vs 31, p <0.05; 2.3 vs 1.3, p=0.003), and a higher bilirubin (2.2 vs 1.5, p=0.003). The median survival was 11 days in Co vs 197 days in HRR vs 467 in LRR. The HRR survival at 30-, 60-, and 90-days was lower than LRR (77%, 72%, 68% vs 89%, 83%, 80%; p=0.02). The median survival of both LVAD groups was statistically superior to Co (p<0.0001). Conclusions: 1) Nearly 25% of the bridge-to-transplant LVAD implantation occurs in HRR who are poor transplant candidates.
4:45 p.m.
856-4 Randomized Comparison of Intra-Aortic Balloon Support Versus a Percutaneous Left Ventricular Assist Device in Patients With Acute Myocardial Infarction Complicated by Cardiogenic Shock
Holger Thiele, Enno Boudriot, Peter Sick, Josef Niebauer, Klaus-Werner Diederich, Rainer Hambrecht, Gerhard Schuler, University of Leipzig -Heart Center, Leipzig, Germany
Background Mortality in cardiogenic shock (CS)following acute myocardial infarction (AMI) remains at an unacceptable level despite PCI and use of intraaortic balloon counterpulsation. Frequently patients succumb to low output before the myocardium is able to recover from the ischemic event. A newly developed percutaneous left ventricular assist device (VAD) (Tandem Heart™ , Cardiac Assist Inc., Pittsburgh, PA, USA) with active circulatory support might decrease mortality.
Methods and results
Since 08/2000 patients in CS after an AMI with revascularization of the infarct related artery were randomized to either IABP (n=20) or percutaneous VAD support (n=19). Predicted mortality probability was similar in both groups (71% vs. 75%, p=n.s.). By VAD support hemodynamic and metabolic parameters could be reversed more effectively in comparison to IABP treatment ( We found similar sensitivity but markedly lower specificity of diagnostic BNP testing than published trials (see Table) . Of the 77 pts without HF, 43 had BNP levels > 100, and 23 had BNP > 200 pg/ml. These patients were elderly, 78% had a pulmonary process, and 82% had infection and sepsis. 82% had evidence of pulmonary hypertension. Conclusion: Serum BNP testing has an increased false positive rate outside the clinical trial setting and may lead to unnecessary and costly cardiac testing. BNP testing has not been studied in patients with edema, however this was a common presentation in our population. The recommended cutoff of 100 may be too low for routine use.
4:15 p.m. OBJECTIVES: We aimed to evaluate the value of BNP levels in predicting subsequent events (readmission & death) in patients admitted with decompensated heart failure (CHF). BACKGROUND: Heart failure is the leading cause of hospital admission among patients over the age of 65 years. Since the BNP levels are increased in ventricular wall stress, we hypothesized that BNP might be useful in assessing outcomes in patients admitted with CHF. METHODS: The BNP Multinational Study was a 7 center, prospective study of 1586 patients who presented with acute dyspnea and had BNP measured upon arrival. A subset of 452 patients with a final adjudicated diagnosis of CHF who underwent echocardiography within 30 days of their visit to the ED were evaluated. We followed 227 patients admitted with CHF. BNP levels were measured at admission and discharge & determined their subsequent adverse events in relation to BNP.RESULT: Of the 227 patients admitted with CHF, 51 events occurred (death: n=9,readmissions: n= 31,unknown cause of death: n=14). The median BNP levels, in patient group with no adverse events during the follow-up period, at admission and discharge was 653 & 450 (pg/ml) respectively in comparison to 961 & 678 (pg/ml) in patient group with adverse events. BNP levels were significantly lower both at the time of admission (p=. 048) and at the time of discharge (p=0.016) in no-adverse event group. The patients in whom BNP decreased during their hospital stay had less adverse events (21.7%)when compared to patients in which the BNP increased (33.3%) (P=0.06). The Receiver Operating Characteristic Curve values for BNP at admission and discharge in predicting events was 0.590 (p=0.035) and 0.609 (p=0.014) respectively, whereas the values for creatinine (0.608) and BUN (0.545) were significant. Also the patients, who had adverse event in the followup after discharge, were found to have significantly longer stay in the hospital at the time of enrollment (median: 8 days vs. 5 days p=0.018 
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